The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

10, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals ... ubamatamab is a CD3-targeting bispecific under investigation for recurrent ovarian cancer and designed to bridge MUC16 on cancer cells with ...

Regeneron’s other costimulatory bispecific development programs, which include candidates against EGFR, MUC16 and CD22, are unaffected and are still making their way through dose escalation.

Regeneron has made a concerted effort ... A peak at phase 1 data of ubamatamab, a bispecific antibody targeting MUC16 and CD3, showed that it held promise among some of the sickest patients.

4, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals ... including a mini-oral on the CD3-targeting bispecific ubamatamab (designed to bridge MUC16 on cancer cells with CD3-expressing T cells ...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the ...

ubamatamab is a CD3-targeting bispecific under investigation for recurrent ovarian cancer and designed to bridge MUC16 on cancer cells with CD3-expressing T cells to facilitate local T-cell ...